Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

ASCO Selects Dramatic Improvement in CLL Care as 'Cancer Advance of the Year'

January 20th 2015

ASCO named the vastly improved outlook for patients with chronic lymphocytic leukemia as its inaugural "Cancer Advance of the Year."

Closing Thoughts: A Cure in Sight for CLL?

January 16th 2015

Treatments and Phenotypes in DLBCL

January 16th 2015

Strategies for Treating Myc-Positive DLBCL

January 16th 2015

Utility of MRD in Mantle Cell Lymphoma

January 16th 2015

Improving Outcomes in Mantle Cell Lymphoma

January 16th 2015

Translating Novel CLL Therapies to Other Types of NHL

January 16th 2015

Indolent Non-Hodgkin's Lymphoma Treatment Selection

January 16th 2015

Assessing Response With Novel Agents in CLL

January 16th 2015

Role of NOTCH1 Mutations in CLL

January 16th 2015

Novel Treatment Approaches to Relapsed/Refractory CLL

January 16th 2015

Strategies for Managing Immune Thrombocytopenia in CLL

January 16th 2015

Maintenance Therapy in Chronic Lymphocytic Leukemia

January 16th 2015

Role of Transplantation in High-Risk CLL

January 16th 2015

Optimizing Treatment With Ibrutinib in High-Risk CLL

January 16th 2015

Safety and Efficacy of Obinutuzumab in CLL

January 16th 2015

First-Line Treatment Selection in CLL

January 16th 2015

Introduction: Upfront Treatment in Patients With CLL

January 16th 2015

FDA Updates Obinutuzumab Frontline CLL Label

December 25th 2014

The FDA has updated the label for obinutuzumab plus chlorambucil to include data from stage 2 of the phase III CLL11 study, which detailed an unprecedented improvement in progression-free survival compared with rituximab plus chlorambucil as a frontline treatment for patients with chronic lymphocytic leukemia.

Frontline Idelalisib Monotherapy Yields High Response Rates in Older Patients With CLL, SLL

December 7th 2014

Idelalisib monotherapy shows activity in treatment-naÃ¯ve patients â‰¥65 years with CLL or SLL, with nearly 90% of patients enrolled in a phase II study demonstrating a partial response.